A mRNA panel for differentiation between acute exacerbation or pneumonia in COPD patients

A mRNA panel for differentiation between acute exacerbation or pneumonia in COPD patients

Introduction: Patients suffering from chronic obstructive pulmonary disease (COPD) are prone to acute exacerbations (AECOPD) or community acquired pneumonia (CAP), both posing severe risk of morbidity and mortality. There is no available biomarker that correctly separates AECOPD from COPD. Howeve...

Cur síos iomlán

Sábháilte in:
Sonraí bibleagrafaíochta
Príomhchruthaitheoirí: Bertrams, Wilhelm, Wilhelm, Jochen, Veeger, Pia-Marie, Hanko, Carolina, Brinke, Kristina auf dem, Klabunde, Björn, Pott, Hendrik, Weckler, Barbara, Greulich, Timm, Vogelmeier, Claus F., Schmeck, Bernd
Formáid: Alt
Teanga:Béarla
Foilsithe / Cruthaithe: Philipps-Universität Marburg 2024
Ábhair:
Medizin
transcriptome
COPD exacerbation
comorbidity
pneumonia
COPD
Medical sciences Medicine
Rochtain ar líne:An téacs iomlán mar PDF
Clibeanna: Cuir clib leis
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
Cur síos
Achoimre:Introduction: Patients suffering from chronic obstructive pulmonary disease (COPD) are prone to acute exacerbations (AECOPD) or community acquired pneumonia (CAP), both posing severe risk of morbidity and mortality. There is no available biomarker that correctly separates AECOPD from COPD. However, because CAP and AECOPD differ in aetiology, treatment and prognosis, their discrimination would be important. Methods: This study analysed the ability of selected candidate transcripts from peripheral blood mononuclear cells (PBMCs) to differentiate between patients with AECOPD, COPD & CAP, and CAP without pre-existing COPD. Results: In a previous study, we identified differentially regulated genes between CAP and AECOPD in PBMCs. In the present new cohort, we tested the potential of selected candidate PBMC transcripts to differentiate at early time points AECOPD, CAP+COPD, and CAP without pre-existing COPD. Expression of YWHAG, E2F1 and TDRD9 held predictive power: This gene set predicted diseases markedly better (model accuracy up to 100%) than classical clinical markers like CRP, lymphocyte count and neutrophil count (model accuracy up to 82%). Discussion: In summary, in our cohort expression levels of YWHAG, E2F1 and TDRD9 differentiated with high accuracy between COPD patients suffering from acute exacerbation or CAP.
Cur síos ar an mír:Gefördert durch den Open-Access-Publikationsfonds der UB Marburg.
DOI:10.3389/fmed.2024.1234068

Míreanna comhchosúla